

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.91120000103100784F)
(Incorporated in the People's Republic of China)

RESOLUTIONS PASSED AT THE 3RD BOARD MEETING FOR FY2023

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

The Company had, on 28 April 2023, duly convened its 3rd Board meeting for the financial year ending 31 December 2023 (“**FY2023**”) by means of live meeting and telephone conference. The said meeting was convened in compliance with the applicable Companies Law, Securities Law and the Articles of Association of the Company, and the following resolutions were discussed and passed by the eight (8) directors out of the full board of eight (8) directors:

1. That, the full text and summary of the first quarter financial statement for FY2023 prepared in accordance with the accounting standards of the People's Republic of China and the International Financial Reporting Standards, be approved.

The Board and management of the Company confirmed that as far as they are aware, there are no material facts the omission of which would make the aforesaid financial statement misleading.

2. That, given that Mr. Zhang Jian (张健) (“**Mr. Zhang**”) has reached the statutory retirement age, the proposed resignation of Mr. Zhang as Deputy General Manager of the Company, be approved.

The Company and the Board would like to extend their appreciation to Mr. Zhang for his services and contributions during his tenure of office as Deputy General Manager.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
28 April 2023